Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART

S. Lambert-Niclot, E. C. George, A. Pozniak, E. White, C. Schwimmer, H. Jessen, M. Johnson, D. Dunn, C. F. Perno, B. Clotet, A. Plettenberg, A. Blaxhult, L. Palmisano, L. Wittkop, V. Calvez, A. G. Marcelin, F. Raffi, Nikos Dedes, Geneviève Chěne, Clotilde AllavenaBrigitte Autran, Andrea Antinori, Raffaella Bucciardini, Stefano Vella, Andrzej Horban, Jose Arribas, Abdel G. Babiker, Marta Boffito, Deenan Pillay, Anton Pozniak, Xavier Franquet, Siegfried Schwarze, Jesper Grarup, Aurélie Fischer, Laura Richert, Cédrick Wallet, François Raffi, Alpha Diallo, Jean Michel Molina, Juliette Saillard, Christiane Moecklinghoff, Hans Jürgen Stellbrink, Remko Van Leeuwen, Jose Gatell, Eric Sandstrom, Markus Flepp, Fiona Ewings, Elizabeth C. George, Fleur Hudson, Gillian Pearce, Romina Quercia, Felipe Rogatto, Randi Leavitt, Bach Yen Nguyen, Frank Goebel, Simone Marcotullio, Navrup Kaur, Peter Sasieni, Christina Spencer-Drake, Tim Peto, Veronica Miller, Fabien Arnault, Céline Boucherie, Delphine Jean, Virginie Paniego, Felasoa Paraina, Elodie Rouch, C. Schwimmer, Malika Soussi, Audrey Taieb, Monique Termote, Guillaume Touzeau, Adam Cursley, Wendy Dodds, Anne Hoppe, Ischa Kummeling, Filippo Pacciarini, Nick Paton, Charlotte Russell, Kay Taylor, Denise Ward, Bitten Aagaard, Marius Eid, Daniela Gey, Birgitte Gram Jensen, Marie Louise Jakobsen, Per O. Jansson, Karoline Jensen, Zillah Maria Joensen, Ellen Moseholm Larsen, Christiane Pahl, Mary Pearson, Birgit Riis Nielsen, Søren Stentoft Reilev, Ilse Christ, Desiree Lathouwers, Corry Manting, Bienvenu Yves Mendy, Annie Metro, Sandrine Couffin-Cadiergues

Research output: Contribution to journalArticleResearchpeer-review

22 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART'. Together they form a unique fingerprint.

Medicine & Life Sciences